Physician profile
Ivan E Silva
NPI 1639666720
$2,067.14
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,473 · 2022: $447 · 2023: $33.17 · 2024: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $147.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $670.25 | 2021-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $295.72 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.11 | 2021-2022 | |
| Abbvie INC. | $138.73 | 2021-2022 | |
| Lilly USA, LLC | $111.64 | 2021-2024 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $110.47 | 2021-2022 | |
| Amarin Pharma, INC. | $108.65 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $107.24 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $73.73 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.44 | 2021-2022 | |
| Optinose US, INC. | $41.94 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $39.73 | 2021 | |
| Glaxosmithkline, LLC. | $37.35 | 2022 | |
| Redhill Biopharma INC. | $24.20 | 2021 | |
| Sumitomo Pharma America, INC. | $24.04 | 2024 | Gemtesa |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $23.90 | 2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.